147 related articles for article (PubMed ID: 9884918)
1. Intracavernous Alprostadil Alfadex--an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study.
Porst H; Buvat J; Meuleman E; Michal V; Wagner G
Int J Impot Res; 1998 Dec; 10(4):225-31. PubMed ID: 9884918
[TBL] [Abstract][Full Text] [Related]
2. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra).
Shabsigh R; Padma-Nathan H; Gittleman M; McMurray J; Kaufman J; Goldstein I
Urology; 2000 Apr; 55(4):477-80. PubMed ID: 10736486
[TBL] [Abstract][Full Text] [Related]
3. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction.
Kunelius P; Lukkarinen O
Int J Impot Res; 1999 Feb; 11(1):21-4. PubMed ID: 10098949
[TBL] [Abstract][Full Text] [Related]
4. Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional actis: a comparative, randomized, crossover, multicenter study.
Shabsigh R; Padma-Nathan H; Gittleman M; McMurray J; Kaufman J; Goldstein I
Urology; 2000 Jan; 55(1):109-13. PubMed ID: 10654905
[TBL] [Abstract][Full Text] [Related]
5. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
Engel JD; McVary KT
Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
Linet OI; Ogrinc FG
N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
[TBL] [Abstract][Full Text] [Related]
7. Sexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomy.
Yiou R; Cunin P; de la Taille A; Salomon L; Binhas M; Lingombet O; Paul M; Abbou C
J Sex Med; 2011 Feb; 8(2):575-82. PubMed ID: 20807323
[TBL] [Abstract][Full Text] [Related]
8. Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction.
Purvis K; Egdetveit I; Christiansen E
Int J Impot Res; 1999 Oct; 11(5):287-99. PubMed ID: 10553808
[TBL] [Abstract][Full Text] [Related]
9. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial.
Montorsi F; Guazzoni G; Strambi LF; Da Pozzo LF; Nava L; Barbieri L; Rigatti P; Pizzini G; Miani A
J Urol; 1997 Oct; 158(4):1408-10. PubMed ID: 9302132
[TBL] [Abstract][Full Text] [Related]
10. Axial penile rigidity as primary efficacy outcome during multi-institutional in-office dose titration clinical trials with alprostadil alfadex in patients with erectile dysfunction. Alprostadil Alfadex Study Group.
Goldstein I; Auerbach S; Padma-Nathan H; Rajfer J; Fitch W; Schmitt L
Int J Impot Res; 2000 Aug; 12(4):205-11. PubMed ID: 11079361
[TBL] [Abstract][Full Text] [Related]
11. [Retrospective study on the incidence and cause of drop-out during intracavernous pharmaco-prosthesis therapy].
Giammusso B; Motta M
Arch Ital Urol Androl; 2002 Mar; 74(1):27-31. PubMed ID: 12053447
[TBL] [Abstract][Full Text] [Related]
12. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment.
Brock G; Tu LM; Linet OI
Urology; 2001 Mar; 57(3):536-41. PubMed ID: 11248634
[TBL] [Abstract][Full Text] [Related]
13. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction.
Porst H
Int J Impot Res; 1997 Dec; 9(4):187-92. PubMed ID: 9442415
[TBL] [Abstract][Full Text] [Related]
14. [The therapeutic and diagnostic potentials of the intra-corpora cavernosa use of alprostadil, Edex, in patients with erectile dysfunction].
Mzo EB; Dmitriev DG
Ter Arkh; 1995; 67(10):45-8. PubMed ID: 8779105
[TBL] [Abstract][Full Text] [Related]
15. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
Asuar Aydillo S
Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
[No Abstract] [Full Text] [Related]
16. [Erection disorders: efficacy and tolerability after 6 months of intracavernous self-injections of alprostadil. Groupe Français d'Etude de l'Alprostadil].
Giuliano F; Blanchet P; Banzet O; Lancrenon S; Benoît G; Jardin A
Presse Med; 1994 Oct; 23(33):1516-21. PubMed ID: 7824478
[TBL] [Abstract][Full Text] [Related]
17. Erectile rehabilitation with intracavernous alprostadil after radical prostatectomy: refusal and dropout rates.
Polito M; d'Anzeo G; Conti A; Muzzonigro G
BJU Int; 2012 Dec; 110(11 Pt C):E954-7. PubMed ID: 23078100
[TBL] [Abstract][Full Text] [Related]
18. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
Tang SF; Chu NK; Wong MK
Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
[TBL] [Abstract][Full Text] [Related]
19. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
Ghanem H; Sherif T; Adbel-Gawad T; Asaad T
Int J Impot Res; 1998 Dec; 10(4):211-4. PubMed ID: 9884916
[TBL] [Abstract][Full Text] [Related]
20. Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea.
Kim SC; Ahn TY; Choi HK; Choi NG; Chung TG; Chung WS; Hwang TK; Hyun JS; Jung GW; Kim CI; Kim JJ; Kim SW; Lee CH; Lee KS; Lee WH; Min KS; Moon KH; Paic JS; Park KS; Park NC; Park YK; Seo JK; Seo KK; Shin JS; Yoon YR; Lee WC
Int J Impot Res; 2000 Apr; 12(2):97-101. PubMed ID: 11052635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
